ClinicalTrials.gg

Program

TQF3250

A development code. Also written as “TQF3250 capsules” and “TQF3250 capsule”.

In Sino Biopharmaceutical's pipeline, GLP-1R激动剂 (口服). Its studies are mostly in Obesity · Hyperglycemia, led by Sino Biopharmaceutical.

Furthest: phase 1, since Dec 5, 20253 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical33 open or runningphase 1since Dec 5, 2025Dec 5, 2025Dec 2026phase 1 · NCT07327281
  • Named in Sino Biopharmaceutical’s own pipeline as TQF3250, phase 1, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 5, 2025First study: phase 1 study in HyperglycemiaFirst studyNCT07327281 · 66 planned · China
  2. Jul 30, 2026Phase 1 study in ObesityNCT07747857 · 72 planned · China
  3. Aug 27, 2026Phase 1 study in OverweightNCT07798284 · 80 planned · China

Ahead

  1. Dec 2026Primary completion: phase 1 study in HyperglycemiaNCT07327281
  2. Apr 2027Primary completion: phase 1 study in OverweightNCT07798284
  3. Jun 2027Primary completion: phase 1 study in ObesityNCT07747857

TargetBeta

“GLP-1R激动剂 (口服)”the company's pipeline, read by Claude · source

Other programs on GLP1R

ProgramCompanyFurthest phaseStudies
SemaglutideruleNovo Nordiskphase 4170
LiraglutideruleNovo Nordiskphase 4116
TirzepatideruleEli Lillyphase 472
dulaglutideruleEli Lillyphase 447
orforglipronruleEli Lillyphase 350
survodutideBoehringer Ingelheimphase 335
zenagamtideNovo Nordiskphase 335
retatrutideruleEli Lillyphase 333
mazdutideruleInnovent Biologicsphase 327
bofanglutideruleGan & Lee Pharmaceuticalsphase 325
berobenatidePfizerphase 323
SafiglipronJiangsu HengRui Medicinephase 319

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07798284Overweight · China1RecruitingApr 202780
NCT07747857Obesity · China1RecruitingJun 202772
NCT07327281Hyperglycemia · China1RecruitingDec 202666

How it is read

Names in the registry

  • “TQF3250 capsules”, 2 entries
  • “TQF3250 capsule”, 1 entry

Codes read as this program: TQF3250.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.